UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 13, 2019
DARÉ BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
 
001-36395
 
20-4139823
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(I.R.S. Employer
Identification No.)

3655 Nobel Drive, Suite 260
San Diego, CA 92122
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code: (858) 926-7655

Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):  
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common stock
DARE
Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company   x




If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   x





Item 5.07
Submission of Matters to a Vote of Security Holders
Our annual meeting of stockholders was held on June 13, 2019. The final results of the matters submitted to a vote of stockholders at such meeting are as follows:
1.
Our stockholders elected the Class II nominees named below to our board of directors to serve for a three-year term to expire at our 2022 annual meeting of stockholders by the votes set forth below:
Nominee
Votes For
Votes Withheld
Abstentions
Broker Non-Votes
Gregory W. Matz
4,883,460
92,021
0
6,871,562
William H. Rastetter, Ph.D.
4,654,985
320,496
0
6,871,562
Robin J. Steele J.D. LLM
4,654,635
320,846
0
6,871,562


2.
Our stockholders ratified the appointment of Mayer Hoffman McCann P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2019 by the votes set forth below:
Votes For
Votes Against
Abstentions
Broker Non-Votes
11,341,328
383,799
121,916
0






SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
 
 
 
 
 
 
DARÉ BIOSCIENCE, INC.
 
 
 
 
Dated: June 14, 2019
 
 
 
By:
 
/s/ Sabrina Martucci Johnson
 
 
 
 
Name:
 
Sabrina Martucci Johnson
 
 
 
 
Title:
 
President and Chief Executive Officer


Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Dare Bioscience Charts.
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Dare Bioscience Charts.